"Ergocalciferols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.
| Descriptor ID |
D004872
|
| MeSH Number(s) |
D04.210.500.247.222.474 D04.210.500.247.808.412 D04.210.500.812.768.462 D10.570.938.439
|
| Concept/Terms |
Vitamin D 2- Vitamin D 2
- Vitamin D2
- D2, Vitamin
- Ergocalciferol
|
Below are MeSH descriptors whose meaning is more general than "Ergocalciferols".
Below are MeSH descriptors whose meaning is more specific than "Ergocalciferols".
This graph shows the total number of publications written about "Ergocalciferols" by people in this website by year, and whether "Ergocalciferols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ergocalciferols" by people in Profiles.
-
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD. J Med Econ. 2020 Mar; 23(3):308-315.
-
Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. J Ren Nutr. 2016 07; 26(4):265-9.
-
Clinical uses of 1-alpha-hydroxy-ergocalciferol. Curr Vasc Pharmacol. 2014 Mar; 12(2):306-12.
-
Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9.
-
Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis. 2012 Jan; 59(1):58-66.
-
Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol. 2010; 32(5):403-13.
-
Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010 Aug; (117):S10-21.
-
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008 Nov; 3(6):1769-76.
-
Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol. 2008; 40(2):427-40.
-
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb; 14(1):18-27.